Patent RU-2765804-C2 (RU)
Title: New applications and methods
Inventor: FANSA-BERTON Paskal Elizabet Rene
IPC: A61P3/04
Filed: 2017-07-25
Granted: 2022-02-03
Abstract: FIELD: medicine; food industry. 
     SUBSTANCE: group of inventions relates to the field of medicine and food industry, namely to a  Fraxinus angustifolia  extract for the use in: (a) treatment of intestinal microbiota dysbiosis associated with obesity and/or metabolic syndrome; (b) treatment or prevention of liver steatosis, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH); (c) treatment or prevention of increased intestinal permeability and/or intestinal hyperpermeability; (d) treatment or prevention of cardiovascular diseases and/or cardiometabolic diseases caused by intestinal dysbiosis; (e) treatment or prevention of mild inflammation; (f) treatment or prevention of atherosclerosis; (g) treatment or prevention of obesity; and/or (h) treatment or prevention of insulin resistance, glucose intolerance, prediabetes and/or diabetes, characterized in that the extract is obtained from  Fraxinus angustifolia  wings, wherein the extract is obtained using a methanol, ethanol, water-methanol or water-ethanol solvent for extraction, and it also relates to a pharmaceutical composition containing the  Fraxinus angustifolia  extract and pharmaceutically acceptable auxiliary substance, and it relates to the use of the  Fraxinus angustifolia  extract and the pharmaceutical composition in: (i) treatment of intestinal microbiota dysbiosis associated with obesity and/or metabolic syndrome; (j) treatment or prevention of liver steatosis, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH); (k) treatment or prevention of increased intestinal permeability and/or intestinal hyperpermeability; (l) treatment or prevention of cardiovascular diseases and/or cardiometabolic diseases caused by intestinal dysbiosis; (m) treatment or prevention of mild inflammation; (n) treatment or prevention of atherosclerosis; (o) treatment or prevention of obesity; and/or treatment or prevention of insulin resistance, glucose intolerance, prediabetes and/or diabetes, and it also relates to a food composition containing the  Fraxinus angustifolia  wing extract and a food-acceptable ingredient, wherein the extract is obtained using a methanol, ethanol, water-methanol or water-ethanol solvent for extraction, and it also relates to the non-therapeutic use of the  Fraxinus angustifolia  wing extract or the food composition in: (i) modulation or correction of intestinal microbiota; (ii) reduction in fat content in the body; and/or (iii) decrease in glucose concentration in blood.  
     EFFECT: group of inventions provides the production of the  Fraxinus angustifolia  wing extract, which has a strong activity in the treatment of intestinal microbiota dysbiosis by modulation or correction of intestinal microbiota, where this activity can have numerous therapeutic and non-therapeutic (for example, cosmetic) applications, and applications in the prevention of diseases, for example, the use of the  Fraxinus angustifolia  wing extract for the treatment of liver steatosis, use for the treatment and prevention of obesity, insulin resistance, glucose intolerance, prediabetes and/or diabetes, atherosclerosis. 
     19 cl, 5 tbl, 5 ex, 14 dwg